JP2019530428A5 - - Google Patents

Download PDF

Info

Publication number
JP2019530428A5
JP2019530428A5 JP2018568300A JP2018568300A JP2019530428A5 JP 2019530428 A5 JP2019530428 A5 JP 2019530428A5 JP 2018568300 A JP2018568300 A JP 2018568300A JP 2018568300 A JP2018568300 A JP 2018568300A JP 2019530428 A5 JP2019530428 A5 JP 2019530428A5
Authority
JP
Japan
Prior art keywords
antibody
pharmaceutical composition
seq
composition according
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018568300A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019530428A (ja
JP7017013B2 (ja
Filing date
Publication date
Priority claimed from US15/201,429 external-priority patent/US10633433B2/en
Application filed filed Critical
Priority claimed from PCT/IB2017/053991 external-priority patent/WO2018007924A2/en
Publication of JP2019530428A publication Critical patent/JP2019530428A/ja
Publication of JP2019530428A5 publication Critical patent/JP2019530428A5/ja
Application granted granted Critical
Publication of JP7017013B2 publication Critical patent/JP7017013B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018568300A 2016-07-02 2017-06-30 抗トランスサイレチン抗体 Active JP7017013B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15/201,429 US10633433B2 (en) 2015-01-28 2016-07-02 Anti-transthyretin antibodies
US15/201,429 2016-07-02
PCT/IB2017/053991 WO2018007924A2 (en) 2016-07-02 2017-06-30 Anti-transthyretin antibodies

Publications (3)

Publication Number Publication Date
JP2019530428A JP2019530428A (ja) 2019-10-24
JP2019530428A5 true JP2019530428A5 (enExample) 2020-08-13
JP7017013B2 JP7017013B2 (ja) 2022-02-08

Family

ID=59506313

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018568300A Active JP7017013B2 (ja) 2016-07-02 2017-06-30 抗トランスサイレチン抗体

Country Status (3)

Country Link
EP (1) EP3478716A2 (enExample)
JP (1) JP7017013B2 (enExample)
WO (1) WO2018007924A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9879080B2 (en) 2015-01-28 2018-01-30 Prothena Biosciences Limited Anti-transthyretin antibodies
US10464999B2 (en) 2015-01-28 2019-11-05 Prothena Biosciences Limited Anti-transthyretin antibodies
US10633433B2 (en) 2015-01-28 2020-04-28 Prothena Biosciences Limited Anti-transthyretin antibodies
BR112020006434A2 (pt) 2017-10-06 2020-11-03 Prothena Biosciences Limited anticorpos anti-transtirretina
KR102581734B1 (ko) 2017-10-06 2023-09-22 네오토프 뉴로사이언스 리미티드 트랜스타이레틴의 검출 방법
BR112020010483A2 (pt) 2017-11-29 2020-10-20 Prothena Biosciences Limited formulação liofilizada de um anticorpo monoclonal contra transtirretina
US20230183329A1 (en) 2020-05-12 2023-06-15 Neurimmune Ag Combination therapy for ttr amyloidosis
EP4237005A4 (en) * 2020-10-28 2024-10-09 Novo Nordisk A/S ANTI-TRANSTHYRETIN ANTIBODIES AND METHODS OF USE THEREOF
KR102623976B1 (ko) * 2021-08-30 2024-01-11 주식회사 뉴보텍 노후배관 보강 및 보수를 위한 보강신축관 및 이 보강신축관을 이용한 노후배관 보수방법
CA3239708A1 (en) 2021-12-03 2023-06-08 Aubin MICHALON Novel potency assay for antibody-based drugs and useful means therefor
WO2024105062A1 (en) 2022-11-15 2024-05-23 Neurimmune Ag Methods for treating or preventing transthyretin-mediated amyloidosis
WO2024240562A1 (en) 2023-05-19 2024-11-28 Neurimmune Ag Novel immunotherapy for musculoskeletal disorders and conditions
WO2025238147A1 (en) 2024-05-15 2025-11-20 Neurimmune Ag Maintenance treatment of cardiac ttr amyloidosis using anti-transthyretin antibodies

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0832981A1 (en) 1987-02-17 1998-04-01 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
DE69230142T2 (de) 1991-05-15 2000-03-09 Cambridge Antibody Technology Ltd. Verfahren zur herstellung von spezifischen bindungspaargliedern
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
CA2150262C (en) 1992-12-04 2008-07-08 Kaspar-Philipp Holliger Multivalent and multispecific binding proteins, their manufacture and use
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5914349A (en) 1994-01-10 1999-06-22 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
DE19539493A1 (de) 1995-10-24 1997-04-30 Thomae Gmbh Dr K Starker homologer Promotor aus Hamster
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
CN100405399C (zh) 1999-02-05 2008-07-23 三星电子株式会社 图像纹理恢复方法及其装置
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
WO2004006955A1 (en) 2001-07-12 2004-01-22 Jefferson Foote Super humanized antibodies
ES2289174T3 (es) 2001-12-28 2008-02-01 Amgen Fremont Inc. Anticuerpos contra el antigeno muc-18.
ES2293096T3 (es) 2002-11-29 2008-03-16 BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG Nuevos genes de la fosfotransferasa de neomicina y procedimiento para la seleccion de celulas recombinantes de produccion elevada.
DE10338531A1 (de) 2003-08-19 2005-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Reklonierung von Produktionszellen
DK1820022T3 (da) 2004-11-10 2009-09-14 Boehringer Ingelheim Pharma Anvendelse af flow-cytometrisk analyse for at optimere cellebanks-strategier af CHO-celler
US8703096B2 (en) 2006-04-21 2014-04-22 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Beta-amyloid PET imaging agents
US20080124760A1 (en) 2006-07-26 2008-05-29 Barbara Enenkel Regulatory Nucleic Acid Elements
EP2099823B2 (en) 2006-12-01 2022-02-09 Seagen Inc. Variant target binding agents and uses thereof
DK2126093T3 (da) 2007-03-02 2013-01-07 Boehringer Ingelheim Pharma Forbedring af proteinfremstilling
EP2031064A1 (de) 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Steigerung von Proteintitern
US9534048B2 (en) 2012-08-24 2017-01-03 University Health Network Antibodies to TTR and methods of use
JP2016514091A (ja) * 2013-02-08 2016-05-19 ミスフォールディング ダイアグノスティクス， インコーポレイテッド トランスサイレチン抗体およびその使用
TWI769570B (zh) * 2015-01-28 2022-07-01 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
TWI718121B (zh) * 2015-01-28 2021-02-11 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體

Similar Documents

Publication Publication Date Title
JP2019530428A5 (enExample)
JP2019532617A5 (enExample)
JP2019530427A5 (enExample)
US20250263493A1 (en) Anti-cd40l antibodies and methods for treating cd40l-related diseases or disorders
JP6234511B2 (ja) アルファシヌクレインを認識するヒト化抗体
JP2020536532A5 (enExample)
JP2018510617A5 (enExample)
RU2007139953A (ru) Антитела к ccr5 и их применение
RU2013115927A (ru) АНТИТЕЛА ПРОТИВ ИЛ-1β И СПОСОБЫ ПРИМЕНЕНИЯ
KR102047248B1 (ko) 침식성 세포의 선택적 제거
CN112424223A (zh) 抗序列相似家族19成员a5的抗体在治疗神经性疼痛中的用途
CN109069622A (zh) 特异性结合人cd40的拮抗性抗体和使用方法
HRP20220918T1 (hr) Anti-transtiretinska antitijela
JP7221352B2 (ja) 抗ｐａｃａｐ抗体
TW200840821A (en) Methods of purifying anti A beta antibodies
EA200970879A1 (ru) Связывающие белки, включающие антитела, производные антител и фрагменты антител, которые специфически связываются с cd154, и их применения
JP2012501670A5 (enExample)
KR20190083356A (ko) 시누클레인병증의 치료를 위한 제제, 용도 및 방법
RU2015136078A (ru) Антитело против с5 и способ предупреждения и лечения обусловленных комплементом заболеваний
CN103097415A (zh) 针对肌生成抑制素6的人源化抗原结合蛋白
JP2011509245A5 (enExample)
TWI713464B (zh) 針對Fcγ受體IIB及Fcε受體的新穎抗體
EP2377555A3 (en) Antibodies against vascular endothelial growth factor receptor-1
WO2014140374A2 (en) Monovalent cd27 antibodies
CN105518026A (zh) 凝集素样氧化型ldl受体1抗体和使用方法